CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.13 CNY | +0.92% |
|
+0.06% | +21.18% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.01 for the current year.
- The stock, which is currently worth 2024 to 0.27 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.18% | 2.49B | D+ | ||
| +14.23% | 69.5B | C+ | ||
| +7.11% | 8.2B | B | ||
| -20.55% | 7.97B | B- | ||
| -4.06% | 7.84B | C | ||
| +2.26% | 4.66B | B- | ||
| +17.12% | 4.32B | B+ | ||
| +1.41% | 4.19B | B- | ||
| -3.02% | 3.89B | B | ||
| +21.42% | 3.62B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 000028 Stock
- Ratings China National Accord Medicines Corporation Ltd.
